Preclinical imaging efforts in models of HER2-positive breast cancer found that the homogeneous 89Zr-pertuzumab exhibited excellent in vivo behavior with improved performance relative to that of the stochastically lysine (isothiocyanate) labeled variant at similar labeling density. Here, ERBB2 is linked to breast carcinoma.